Combining Active and Passive DNA Hypomethylation

PHASE2RecruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Myelodysplastic SyndromesAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia
Interventions
DIETARY_SUPPLEMENT

Vitamin C

Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.

DIETARY_SUPPLEMENT

Placebo

Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.

Trial Locations (10)

2100

RECRUITING

Rigshospitalet, Copenhagen

2730

RECRUITING

Herlev University Hospital, Copenhagen

5000

ACTIVE_NOT_RECRUITING

Odense University Hospital, Odense

9100

RECRUITING

Aalborg University Hospital, Aalborg

Unknown

RECRUITING

Aarhus University Hospital, Aarhus

TERMINATED

Zealand University Hospital, Roskilde

RECRUITING

Sahlgrenska University Hospital, Gothenburg

RECRUITING

Skåne University Hospital, Lund

RECRUITING

Karolinska University Hospital, Stockholm

RECRUITING

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Van Andel Institute - Stand Up To Cancer Epigenetics Dream Team

UNKNOWN

collaborator

Karolinska University Hospital

OTHER

collaborator

Skane University Hospital

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

University of Southern California

OTHER

collaborator

Imperial College London

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

Zealand University Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Technical University of Denmark

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Uppsala University Hospital

OTHER

lead

Kirsten Grønbæk

OTHER